anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
Methods and compositions for treatment of halitosis are provided. Devices and methods, such as a palatal patch, including a tablet or strip having a bioadhesive component and active ingredients are further provided. The bioadhesive component allows for the palatal patch to be attached to an upper palate, and for the active component to be released into the oral cavity and/or GI tract. Compositions for the active ingredient include composition for treatment of halitosis, anti-acids, vitamins, anti-smoking agents, etc. A herbal composition for treatment of halitosis including  Echinacea , Lavender, Mastic Gum and Sage and a method of manufacturing a medicine from the herbal composition are provided as well. A device for delivery of the palatal patch to the upper palate including a housing and piston is also provided.
The long-term goals of this research are to quantify patient-specific changes in neuromuscular control in order to optimize treatment planning and improve mobility for individuals with cerebral palsy (CP). As a first step, the aims of this proposal are to evaluate neuromuscular control before and after one of the most common treatments for individuals with CP, orthopaedic surgery. The investigators will evaluate if patient-specific measures of neuromuscular control, based upon the framework of muscle synergies, can predict improvements in walking ability after surgery. Further, investigators will determine whether neuromuscular control changes after surgery and if these changes contribute to improvements in movement. To achieve these goal the investigators will implement and test new tools to quantify neuromuscular control which integrate clinical gait analysis and two computational techniques: synergy analysis and dynamic musculoskeletal simulation. This research will provide the foundation to use measures of altered neuromuscular control to inform treatment planning, develop alternative treatments, and improve mobility in CP and other neurologic disorders.
Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
To investigate ciliochoroidal detachment (CCD) frequency and risk factors after performing goniotomy with the Kahook Dual Blade (KDB). The presence of CCD was examined using anterior-segment optical coherence tomography at postoperative day (POD) 1, month 1, and month 2 in 91 eyes of patients who underwent goniotomy with KDB. Intraocular pressure (IOP) was also measured at POD 1, POD 7, month 1 and month 2. A generalized linear mixed model analysis was used to compare the age, gender, axial length, central corneal thickness, surgical procedure (combined or single), operators (K.H. or H.O.), glaucoma type and preoperative IOP between the groups. Factors were selected from the variants when there was a probability value of less than 0.05. CCD was detected in 18 eyes (19.7%) at POD 1. For postoperative IOP, no significant differences were observed between the CCD and non-CCD groups. However, the IOP on POD 1 in the CCD that was associated with the anterior chamber group (7.7 ± 3.0 mmHg) was significantly lower than that in the non-CCD group (15.3 ± 0.9 mmHg) (P = 0.02). Mixed-effects model analysis demonstrated that the surgical procedure (combined) and operator (H.O.) were significantly associated with the higher incidence of CCD. Approximately one-fifth of all eyes exhibited CCD after goniotomy with KDB. Combining cataract surgery and goniotomy with KDB and the intraoperative procedure during the goniotomy with KDB were all found to be risk factors for developing CCD.
Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
OBJECTIVE: To explore the different processes of the themes and emotional evolution of various stakeholders in the network public opinion of sudden public health emergencies at different stages of the public opinion evolution lifecycle.
METHODS: This paper proposes a cross-platform analysis method for online public opinion during the public health emergencies based on stakeholders. Firstly, data from multiple platforms are collected and integrated. Secondly, stakeholders are categorized and the stages of public opinion evolution are determined based on stakeholder theory and lifecycle theory. Finally, the Latent Dirichlet Allocation (LDA)+Word2vec model and Convolutional Neural Network (CNN) model are used to analyze the themes and emotional evolution of stakeholders during different stages of public opinion evolution.
RESULTS: There are differences in the evolution patterns of different types of stakeholders. The evolution process of stakeholders' focus points exhibits a two-stage transition from concentration to divergence. The focus points of stakeholders are closely associated with their respective social domains. The emotions of the public undergo a three-stage process of positive-negative-positive change.
CONCLUSIONS: This study can provide a reference for the government to have a more comprehensive understanding of the development trend of public opinion and reduce the negative impact of public opinion.
This is a cluster randomized trial comparing two ways to better align Veterans' preferences and treatments for AAA: (1) a validated decision aid describing AAA repair types with a survey measuring Veterans' preference for repair type -- versus (2) the survey alone. Enrolled Veterans will be candidates for either endovascular or open repair, and be followed at VA hospitals by vascular surgery teams who regularly perform both types of repair. In Aim 1, the investigators will determine Veterans' preferences for endovascular or open repair and identify domains associated with each repair type. In Aim 2, the investigators will compare agreement between Veterans' preferences and repair type between the decision aid+survey and survey-alone groups. In Aim 3, the investigators will investigate the facilitators and barriers of implementing a decision aid in a VA surgical clinic. The investigators will identify factors associated with agreement. The investigators' findings will be reported to the National Surgery Office Vascular Surgery Advisory Board to help ensure Veterans' preferences remain at the center of AAA treatment decisions. The investigators have recruited 20 VA Medical Centers and their vascular surgery teams to participate in this trial.
The present invention relates to a medical composition for treating hyperplasia of mammary glands. The medical composition has the raw materials of prepared frankincense, prepared myrrh, angelica, red sage root, red peony root, seaweed, kelp, deglued antler, bupleurum root, prepared benzoin, tangerine seed, etc. which are prepared into a common oral preparation (such as pills, granules, tablets, capsuless, oral liquid, etc.) by a conventional traditional Chinese medicine preparation method. The present invention has the main functions of activating blood circulation, dissipating blood stasis and alleviating pain, and has the auxiliary functions of regulating Chong and Ren meridians, removing stasis, dispersing the stagnated liver qi to relieve qi stagnation and regulating the vital energy to remove stasis, so the goal of regulating channels of the liver and the gallbladder to guide the medicine to directly reach affected parts. Clinical tests prove that the present invention has the conspicuous effect on relieving breast pain and reducing breast lump, and has the total effective rate of 83.3%.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a bighead atractylodes rhizome and monkshood decoction, wherein the raw materials of active ingredients comprise: 6 parts by weight of bighead atractylodes rhizome, 10 parts by weight of monkshood, 3 parts by weight of licorice, 4.5 parts by weight of ginger, and 6 parts by weight of Chinese-date. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of bighead atractylodes rhizome and monkshood decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property, and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of bighead atractylodes rhizome and monkshood decoction can be realized simultaneously, and the medicament can be separately taken in four time slices according to the midnight-noon ebb-flow and qi and the blood flowing rule of a human body. The integrated new formulation of bighead atractylodes rhizome-monkshood decoction can be further prepared into films and transdermal agents, which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body, and can be directly absorbed through skin.
Primary hepatic sarcomatoid carcinoma is a very aggressive tumor, representing 0.4-0.7% of all primary hepatic neoplasms. The disease is associated with liver disease due to hepatotropic viruses and is more prevalent in Asians. Histology shows sarcomatous and carcinoma components. It does not have pathognomonic clinical or imaging characteristics and its diagnosis is based on the pathological and immunohistochemistry findings. Surgery could prolong survival in localized stages. We report the case of a 72-year-old Korean patient with a history of chronic liver disease due to B virus, who was diagnosed with primary hepatic sarcomatoid carcinoma with bone and lymph node metastases.
PROBLEM TO BE SOLVED: To obtain a release agent which has excellent drying and release properties and is used for the formation of a jacket crown of a rigid resin on a plaster abutment tooth model by forming a release agent set consisting of an aq. suspension of a polymer having rubber elasticity and an org. solvent soln. contg. a specific silicon compd, etc. SOLUTION: The release agent set consisting of two agents; (A) the aq. suspension of the polymer having the rubber elasticity and (B) an org. solvent soln. contg. the silicon compd. expressed by formula: R<1> n -Si-(RO<2> )4-n (where, R<1> , R<2> are alkyl groups or aryl groups, (n) is an integer from 1 to 3) and/or silicone oil as well as sucrose fatty acid ester is used in the release agent to be previously applied on a plaster model in order to facilitate the sepn. of the rigid resin jacket crown after curing from the plaster model for the purpose of crown prosthesis. After the liquid (A) is applied on the part corresponding to the inside surface of the jacket crown exclusive of the margin part of the plaster abutment tooth, the soln. (B) is applied on the margin part.
This will be a single centre, controlled, open label, randomized, three-treatment, three-period, cross-over design in participants with full upper and full lower dentures. Each treatment period will consist of one day of testing with at least two days between adjacent treatment visits. This study will consist of four visits: Visit 1 - Screening Visit; Visit 2 - Treatment 1 Visit; Visit 3 - Treatment 2 Visit and Visit 4 - Treatment 3 Visit. (Participants will use Test product (denture adhesive) applied to the dentures either in a pattern consistent with standard application or applied to the dentures in a pattern of continuous strips. Participants will also use no adhesive as a control. Participants will cross-over between treatments so that all participants will participate in all 3 treatment arms. An hour after the participant has worn their denture, they will chew a portion of peanuts in a controlled manner. The peanuts that migrate under the denture during this chewing procedure will be collected, washed, dried and weighed. Participant will also answer a short questionnaire on the procedure and record the number of times their denture dislodged during the chewing procedure. The study hypothesis is that this methodology will enable comparisons between denture adhesives and no adhesive to demonstrate the effectiveness of denture adhesives at restricting food ingress under dentures during eating.
The invention provides a wrinkle-removing and anti-aging composition, which comprises vitamin C or a derivative thereof and nicotinamide mononucleotide, or comprises vitamin C or a derivative thereof and borneol, or comprises nicotinamide mononucleotide and borneol, or comprises vitamin C or a derivative thereof, nicotinamide mononucleotide and borneol. Or taurine is also included in the composition. The invention also provides a preparation method and application of the composition. The research of the invention shows that the wrinkle-removing anti-aging composition can effectively remove aging cells and promote skin wrinkle repair under a certain dosage, and has obviously better anti-aging effect than single component. Animal experiment results also show that the compound can reduce damage to the back skin of mice, reduce skin aging and inflammation, increase collagen fiber synthesis, and restore UVB-induced epidermal thickening. In summary, it is believed that the ratio of the combination compounds is effective in inhibiting photoaging of the skin caused by UVB exposure, resulting in skin firmness and elasticity that is more closely related to healthy skin conditions.
Wait-listed control group will be instructed to continue behavior "as-usual". They will receive access to the HEALED website at the end of the 12-week intervention period.
The disclosed systems and methods provide Patient Care Unit (PCU) order confirmation. A method may include authorizing a user to operate a drug delivery device. The method may also include retrieving a user history associated with the user in response to the authorization, wherein the user history includes one or more medication dispense records for the pending medication. The method may further include determining one or more medication order candidates for the current administration based on a context including a user history. The method may also include presenting a user interface for confirming the medication order from the one or more medication order candidates. The method may further include configuring at least one parameter of the drug delivery device based on the confirmed medication order received from the user interface.
EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
Individuals with peripheral artery disease (PAD) have been shown to have poorer cardiovascular health outcomes than the general population. It is believed that the number of people living with PAD is greatly underestimated and furthermore, mortality due to the most severe form of PAD - critical limb ischemia - is increasing. There is a growing body of evidence that the presence of cardiovascular risk factors leads to the imbalance of circulating regenerative cells. The aggregate impact of this regenerative cell exhaustion phenotype is an increased risk of adverse events and progression of disease states.

PAD-VRCE is an observational, cross-sectional, two-arm cohort study aimed at determining the differences in the progenitor cell profiles in the blood of individuals with PAD in comparison to individuals without PAD. We hypothesize that people with PAD will exhibit depleted levels of these progenitor cells defined as vascular regenerative cell exhaustion. VRCE impacts the function of anti-inflammatory cells and associated repair mechanisms within blood vessels, and may contribute to the differential long term outcomes between the two groups.
The invention discloses octapeptide SCCSCDED and an application thereof. The amino acid sequence of synthetic peptide is shown as follows: Ser-Cys-Cys-Ser-Cys-Asp-Glu-Asp which is abbreviated as SCCSCDED, the molecular weight is 861.2 and the purity is 96.2%. A polypeptide synthesis instrument is adopted in polypeptide, and a solid-phase synthesis method is used for synthesis. Antitumor activity in vitro is detected, so that the polypeptide has a certain inhibitory effect on hepatoma carcinoma cells HepG-2 and breast cancer cells MCF-7 within the range of 100-500 micrograms/mL. The in-vitro proliferation inhibition rate to the HepG-2 and the in-vitro proliferation inhibition rate to the MCF-7 are 48.49% and 61.86% respectively at the concentration of 500 micrograms/mL. The synthetic peptide with the antitumor activity in vitro can be applied to the field of bio-pharmaceuticals.
Personal care compositions comprise (a) from about 0.01 wt. % to about 10 wt. % of a galactomannan polymer derivative having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, the galactomannan polymer derivative selected from a cationic galactomannan polymer derivative and an amphoteric galactomannan polymer derivative having a net positive charge, wherein the cationic galactomannan polymer has a molecular weight from about 1,000 to about 10,000,000 and a cationic charge density from about 0.7 meq/g to about 7 meq/g; (b) from about 5 wt. % to about 35 wt. % of an anionic surfactant system, the anionic surfactant system comprising at least one anionic surfactant and having an ethoxylate level and an anion level, (i) wherein the ethoxylate level is from about 1 to about 6, and (ii) wherein the anion level is from about 1.5 to about 6; and (c) an aqueous carrier. Personal care compositions as described above further comprise from about 0.01 wt. % to about 10 wt. % of one or more conditioning agents. Methods of treating hair or skin comprise applying the personal care compositions as described above to the hair or skin and rinsing the hair or skin.
The objective of this meta-epidemiological study was to explore the impact of attrition rates on treatment effect estimates in randomised trials of chronic inflammatory diseases (CID) treated with biological and targeted synthetic disease-modifying drugs. We sampled trials from Cochrane reviews. Attrition rates and primary endpoint results were retrieved from trial publications; Odds ratios (ORs) were calculated from the odds of withdrawing in the experimental intervention compared to the control comparison groups (i.e., differential attrition), as well as the odds of achieving a clinical response (i.e., the trial outcome). Trials were combined using random effects restricted maximum likelihood meta-regression models and associations between estimates of treatment effects and attrition rates were analysed. From 37 meta-analyses, 179 trials were included, and 163 were analysed (301 randomised comparisons; n = 62,220 patients). Overall, the odds of withdrawal were lower in the experimental compared to control groups (random effects summary OR = 0.45, 95% CI, 0.41-0.50). The corresponding overall treatment effects were large (random effects summary OR = 4.43, 95% CI 3.92-4.99) with considerable heterogeneity across interventions and clinical specialties (I2 = 85.7%). The ORs estimating treatment effect showed larger treatment benefits when the differential attrition was more prominent with more attrition in the control group (OR = 0.73, 95% CI 0.55-0.96). Higher attrition rates from the control arm are associated with larger estimated benefits of treatments with biological or targeted synthetic disease-modifying drugs in CID trials; differential attrition may affect estimates of treatment benefit in randomised trials.
FIELD: therapeutic products. SUBSTANCE: spherical or lens-shaped granules with unique maximum diameter 0.5 to 4 mm consist of, wt %: at least one biologically-active compound, 0.1-87; at least one water-insoluble polymer, 5-50; at least one lipophilic component as plasticizer for above polymer, 5-45; naturally occurred or semisynthetic polymer gel former, 0-50; and one or several standard adjuvants. Gel former is a water-soluble cellulose derivative or water-soluble polysaccharide or their mixtures. Granules are prepared by extruding molten mixture of components at 50 to 200 C involving continuous shaping. EFFECT: enabled controlled complete release of active principle according to delayed profile. 8 cl, 4 tbl
1055 healthy term infants born in 2016-2018 mainly at the capital region of Finland, and their parents. Fecal samples collected from infants and their parents. Electronic questionnaires on a weekly basis during the first 4 months of life, thereafter less frequently. Focus on diet, well-being and health and social manners. At one-year and at two-years comprehensive questionnaires including development and cognition. Parental stress evaluation included.